{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:59:00Z","timestamp":1792897140081,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bbagen.2019.129437","type":"journal-article","created":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T10:38:33Z","timestamp":1568457513000},"page":"129437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Progress in the understanding and treatment of Fabry disease"],"prefix":"10.1016","volume":"1864","author":[{"given":"James J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Kanack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Dahms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \u201cangio-keratoma\u201d","volume":"10","author":"Anderson","year":"1898","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbagen.2019.129437_bb0010","first-page":"187","article-title":"Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)","volume":"43","author":"Fabry","year":"1898","journal-title":"Archiv f\u00fcr Dermatologie und Syphilis, Berlin."},{"key":"10.1016\/j.bbagen.2019.129437_bb0015","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.bbagen.2019.129437_bb0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bbagen.2019.129437_bb0025","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","article-title":"Characterization of pain in fabry disease","volume":"30","author":"Uceyler","year":"2014","journal-title":"Clin. J. Pain"},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","article-title":"Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder","volume":"53","author":"Samiy","year":"2008","journal-title":"Surv. Ophthalmol."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajpath.2014.11.004","article-title":"Alpha-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease","volume":"185","author":"Bangari","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbagen.2019.129437_bb0040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39300","article-title":"Characterization of small fiber pathology in a mouse model of Fabry disease","volume":"7","author":"Hofmann","year":"2018","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.bbagen.2019.129437_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99171","article-title":"Neuropathic pain in a Fabry disease rat model","volume":"3","author":"Miller","year":"2018","journal-title":"JCI Insight."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0050","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1038\/s41598-019-45837-1","article-title":"Rats deficient in alpha-galactosidase A develop ocular manifestations of Fabry disease","volume":"9","author":"Miller","year":"2019","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.bbagen.2019.129437_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.heares.2007.08.009","article-title":"Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease","volume":"234","author":"Noben-Trauth","year":"2007","journal-title":"Hear. Res."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anl.2009.08.005","article-title":"Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry disease","volume":"37","author":"Sakurai","year":"2010","journal-title":"Auris Nasus Larynx"},{"issue":"11","key":"10.1016\/j.bbagen.2019.129437_bb0065","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1096\/fj.201800771R","article-title":"Alpha-galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease","volume":"33","author":"Miller","year":"2019","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bbagen.2019.129437_bb0075","doi-asserted-by":"crossref","first-page":"e33743","DOI":"10.1371\/journal.pone.0033743","article-title":"Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease","volume":"7","author":"Nguyen Dinh Cat","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin. Genet."},{"issue":"12","key":"10.1016\/j.bbagen.2019.129437_bb0085","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","article-title":"Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density","volume":"9","author":"Mersebach","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.bbagen.2019.129437_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"14","key":"10.1016\/j.bbagen.2019.129437_bb0095","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000001450","article-title":"Clinical prodromes of neurodegeneration in Anderson-Fabry disease","volume":"84","author":"Lohle","year":"2015","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual. Life Res."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.bbagen.2019.129437_bb0110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bbagen.2019.129437_bb0115","series-title":"Fabry Disease","author":"Mehta","year":"2002"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.bbagen.2019.129437_bb0125","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"Elliott","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbagen.2019.129437_bb0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bbagen.2019.129437_bb0140","author":"Cooper"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12881-016-0309-z","article-title":"Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles","volume":"17","author":"Oder","year":"2016","journal-title":"BMC Med. Genet."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female","volume":"22","author":"Rodriguez-Mari","year":"2003","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.bbagen.2019.129437_bb0155","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0160","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1074\/mcp.RA118.000967","article-title":"Targeted analysis of lysosomal directed proteins and their sites of Mannose-6-phosphate modification","volume":"18","author":"Caval","year":"2019","journal-title":"Mol Cell Proteomics."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0180","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0185","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0006-291X(77)80136-8","article-title":"The identification of alpha-galactosidase B from human liver as an alpha-N-acetylgalactosaminidase","volume":"77","author":"Dean","year":"1977","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbagen.2019.129437_bb0190","author":"Carbohydrate Active enZYmes Database"},{"issue":"20","key":"10.1016\/j.bbagen.2019.129437_bb0195","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1016\/S0021-9258(19)86664-4","article-title":"Studies on human liver alpha-galactosidases. II. Purification and enzymatic properties of alpha-galactosidase B (alpha-N-acetylgalactosaminidase)","volume":"254","author":"Dean","year":"1979","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbagen.2019.129437_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1194\/jlr.M100423-JLR200","article-title":"Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases","volume":"43","author":"Asfaw","year":"2002","journal-title":"J. Lipid Res."},{"issue":"33","key":"10.1016\/j.bbagen.2019.129437_bb0205","doi-asserted-by":"crossref","first-page":"25315","DOI":"10.1074\/jbc.M002630200","article-title":"Cloning of Gb3 synthase, the key enzyme in globo-series glycosphingolipid synthesis, predicts a family of alpha 1, 4-glycosyltransferases conserved in plants, insects, and mammals","volume":"275","author":"Keusch","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2019.129437_bb0210","series-title":"Essentials of Glycobiology","first-page":"125","article-title":"Glycosphingolipids","author":"Schnaar","year":"2015"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21307\/immunohematology-2019-120","article-title":"P1PK: the blood group system that changed its name and expanded","volume":"29","author":"Hellberg","year":"2013","journal-title":"Immunohematology."},{"issue":"20","key":"10.1016\/j.bbagen.2019.129437_bb0220","doi-asserted-by":"crossref","first-page":"15152","DOI":"10.1074\/jbc.M909620199","article-title":"Molecular cloning of globotriaosylceramide\/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids","volume":"275","author":"Kojima","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.bbagen.2019.129437_bb0225","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1074\/jbc.M000728200","article-title":"Cloning and expression of the histo-blood group Pk UDP-galactose: Ga1beta-4G1cbeta1-cer alpha1, 4-galactosyltransferase. Molecular genetic basis of the p phenotype","volume":"275","author":"Steffensen","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bbagen.2019.129437_bb0230","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.febslet.2009.11.089","article-title":"Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect","volume":"584","author":"Lingwood","year":"2010","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0235","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0021-9258(19)75706-8","article-title":"Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1","volume":"262","author":"Lindberg","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2019.129437_bb0240","series-title":"Essentials of Glycobiology","first-page":"481","article-title":"Microbial lectins: hemagglutinins, adhesins, and toxins","author":"Nizet","year":"2015"},{"issue":"15","key":"10.1016\/j.bbagen.2019.129437_bb0245","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1074\/jbc.M600057200","article-title":"Targeted disruption of Gb3\/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins","volume":"281","author":"Okuda","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bbagen.2019.129437_bb0250","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/507705","article-title":"Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli","volume":"194","author":"Cilmi","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbagen.2019.129437_bb0255","series-title":"Fabry Disease","first-page":"39","article-title":"Subcellular, cellular, and organ pathology of Fabry disease","author":"Elleder","year":"2010"},{"key":"10.1016\/j.bbagen.2019.129437_bb0260","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10545-017-0107-6","article-title":"Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression","volume":"41","author":"Meng","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int."},{"issue":"29","key":"10.1016\/j.bbagen.2019.129437_bb0285","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1074\/jbc.M702436200","article-title":"Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice","volume":"282","author":"Shu","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0290","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ki.2008.576","article-title":"Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy","volume":"75","author":"Thomaidis","year":"2009","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.bbagen.2019.129437_bb0295","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/auto.6.5.11943","article-title":"Autophagosome maturation is impaired in Fabry disease","volume":"6","author":"Chevrier","year":"2010","journal-title":"Autophagy."},{"issue":"5","key":"10.1016\/j.bbagen.2019.129437_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry's disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bbagen.2019.129437_bb0305","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ki.2012.337","article-title":"Autophagy protects proximal tubular cells from injury and apoptosis","volume":"82","author":"Kaushal","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"Lucke","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.bbagen.2019.129437_bb0315","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy","volume":"54","author":"Heo","year":"2017","journal-title":"J. Med. Genet"},{"issue":"13","key":"10.1016\/j.bbagen.2019.129437_bb0320","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol Genet Metab."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0330","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2019.129437_bb0335","article-title":"Tumor necrosis factor-alpha links heat and inflammation with Fabry pain","author":"Uceyler","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbagen.2019.129437_bb0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fmed.2018.00147","article-title":"Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis","volume":"5","author":"Mosevoll","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0345","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2004-01-0107","article-title":"Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow","volume":"104","author":"Bernardo","year":"2004","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.bbagen.2019.129437_bb0350","doi-asserted-by":"crossref","first-page":"14196","DOI":"10.1073\/pnas.95.24.14196","article-title":"Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway","volume":"95","author":"Xia","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0355","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.kint.2018.08.033","article-title":"Alpha-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease","volume":"95","author":"Kang","year":"2019","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0360","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.bbagen.2019.129437_bb0365","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/jcp.25807","article-title":"Impact of lysosomal storage disorders on biology of mesenchymal stem cells: evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes","volume":"232","author":"Squillaro","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.bbagen.2019.129437_bb0370","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0375","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.bbagen.2019.129437_bb0380","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Nino","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"20","key":"10.1016\/j.bbagen.2019.129437_bb0385","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Nino","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbagen.2019.129437_bb0390","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci Lett."},{"issue":"6","key":"10.1016\/j.bbagen.2019.129437_bb0395","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2008.09.001","article-title":"Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice","volume":"33","author":"Rodrigues","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.bbagen.2019.129437_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108641","article-title":"Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice","volume":"9","author":"Lakoma","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2019.129437_bb0410","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916663729","article-title":"Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model","volume":"12","author":"Lakoma","year":"2016","journal-title":"Mol Pain"},{"key":"10.1016\/j.bbagen.2019.129437_bb0415","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916646379","article-title":"Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development","volume":"12","author":"Uceyler","year":"2016","journal-title":"Mol. Pain"},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0420","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0425","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jb\/mvq125","article-title":"Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease","volume":"149","author":"Shiozuka","year":"2011","journal-title":"J Biochem."},{"issue":"3","key":"10.1016\/j.bbagen.2019.129437_bb0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","article-title":"A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis","volume":"456","author":"Taguchi","year":"2013","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bbagen.2019.129437_bb0445","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0450","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: dose matters","volume":"25","author":"Warnock","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.bbagen.2019.129437_bb0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet."},{"key":"10.1016\/j.bbagen.2019.129437_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2019.03.010","article-title":"Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial","author":"Ramaswami","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"36","key":"10.1016\/j.bbagen.2019.129437_bb0465","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0470","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","author":"van der Veen","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0475","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbagen.2019.129437_bb0480","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0485","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0490","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.bbagen.2019.129437_bb0495","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","article-title":"Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation","volume":"105","author":"Abe","year":"2000","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0500","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1523-1755.2000.00864.x","article-title":"Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase","volume":"57","author":"Abe","year":"2000","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.bbagen.2019.129437_bb0505","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0510","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/03009734.2011.641609","article-title":"Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution","volume":"117","author":"Machaczka","year":"2012","journal-title":"Ups J Med Sci."},{"issue":"7","key":"10.1016\/j.bbagen.2019.129437_bb0515","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases","volume":"55","author":"Shayman","year":"2014","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.bbagen.2019.129437_bb0520","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bbagen.2019.129437_bb0525","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.plipres.2013.02.001","article-title":"Cell-specific in vivo functions of glycosphingolipids: lessons from genetic deletions of enzymes involved in glycosphingolipid synthesis","volume":"52","author":"Jennemann","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbagen.2019.129437_bb0530","first-page":"1","article-title":"An update on gene therapy for lysosomal storage disorders","author":"Nagree","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbagen.2019.129437_bb0535","first-page":"S83","article-title":"AAV gene therapy for the treatment of Fabry disease: A novel capsid with improved tropism to heart, kidney and CNS and improved GLA expression","volume":"126","author":"Kevany","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0540","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol Ther."},{"issue":"4","key":"10.1016\/j.bbagen.2019.129437_bb0545","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"8","key":"10.1016\/j.bbagen.2019.129437_bb0550","doi-asserted-by":"crossref","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active alpha-Galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bbagen.2019.129437_bb0555","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human alpha-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416519302235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416519302235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:05:25Z","timestamp":1759637125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416519302235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0304416519302235"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2019.129437","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the understanding and treatment of Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2019.129437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129437"}}